Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 4/2014

01-04-2014 | Research Article

Lack of association between MTHFD1 G401A polymorphism and ovarian cancer susceptibility

Authors: Yuling Cui, Yanhua Jing, Zihan Sun

Published in: Tumor Biology | Issue 4/2014

Login to get access

Abstract

Published studies on the association between methylenetetrahydrofolate dehydrogenase 1 (MTHFD1) G401A polymorphism and ovarian cancer risk have yielded conflicting results. In order to derive a more precise estimation of the relationship between G401A polymorphism and ovarian cancer risk, the present meta-analysis was performed. All eligible studies on G401A polymorphism and ovarian cancer risk were collected from the PubMed and the Cochrane Library. Statistical analyses were performed by Review Manage 5.0 and Stata 11.0. Our analysis suggested that G401A polymorphism was not associated with ovarian cancer risk when using additive (odds ratio (OR) = 1.72, 95 % confidence interval (CI) = 1.34–2.20, P < 0.0001), recessive (OR = 1.46, 95 % CI = 1.21–1.77, P < 0.0001), dominant (OR = 1.36, 95 % CI = 1.10–1.69, P = 0.004), and allelic models (OR = 1.30, 95 % CI = 1.15–1.47, P < 0.0001) to analyze the data. This meta-analysis suggests that G401A polymorphism might not be a risk factor for ovarian cancer risk. However, further well-designed studies are required to confirm our findings.
Literature
1.
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71–96.PubMedCrossRef
2.
Sabatier R, Gonçalves A, Bertucci F, Capiello MA, Rousseau F, Lambaudie E, et al. Are there candidates for high-dose chemotherapy in ovarian carcinoma? J Exp Clin Cancer Res. 2012;31:87.PubMedCentralPubMedCrossRef
3.
4.
Hassan MK, Watari H, Han Y, Mitamura T, Hosaka M, Wang L, et al. Clusterin is a potential molecular predictor for ovarian cancer patient’s survival: targeting clusterin improves response to paclitaxel. J Exp Clin Cancer Res. 2011;30:113.PubMedCentralPubMedCrossRef
5.
Plotti F, Capriglione S, Terranova C, Montera R, Aloisi A, Damiani P, et al. Does HE4 have a role as biomarker in the recurrence of ovarian cancer? Tumor Biol. 2012;33:2117–23.CrossRef
6.
Deng B, Zhang S, Miao Y, Han Z, Zhang X, Wen F, et al. Adrenomedullin expression in epithelial ovarian cancers and promotes HO8910 cell migration associated with upregulating integrin α5β1 and phosphorylating FAK and paxillin. J Exp Clin Cancer Res. 2012;31:19.PubMedCentralPubMedCrossRef
7.
Raji R, Guzzo F, Carrara L, Varughese J, Cocco E, Bellone S, et al. Uterine and ovarian carcinosarcomas overexpressing Trop-2 are sensitive to hRS7, a humanized anti-Trop-2 antibody. J Exp Clin Cancer Res. 2011;30:106.PubMedCentralPubMedCrossRef
8.
Zhang H, Ma H, Li L, Zhang Z, Xu Y. Association of methylenetetrahydrofolate dehydrogenase 1 polymorphisms with cancer: a meta-analysis. PLoS One. 2013;8:e69366.PubMedCentralPubMedCrossRef
9.
10.
Zhang H, Xu Y, Zhang Z, Liu R, Ma B. Association between COX-2 rs2745557 polymorphism and prostate cancer risk: a systematic review and meta-analysis. BMC Immunol. 2012;13:14.PubMedCentralPubMedCrossRef
11.
12.
Ma E, Iwasaki M, Junko I, Hamada GS, Nishimoto IN, Carvalho SM, et al. Dietary intake of folate, vitamin B6, and vitamin B12, genetic polymorphism of related enzymes, and risk of breast cancer: a case–control study in Brazilian women. BMC Cancer. 2009;9:122.PubMedCentralPubMedCrossRef
13.
Friso S, Choi SW. Gene-nutrient interactions in one-carbon metabolism. Curr Drug Metab. 2005;6:37–46.PubMedCrossRef
14.
Linhart HG, Troen A, Bell GW, Cantu E, Chao WH, Moran E, et al. Folate deficiency induces genomic uracil misincorporation and hypomethylation but does not increase DNA point mutations. Gastroenterology. 2009;136:227–35.PubMedCentralPubMedCrossRef
15.
Hum DW, Bell AW, Rozen R, MacKenzie RE. Primary structure of a human trifunctional enzyme: isolation of a cDNA encoding methylenetetrahydrofolate-dehydrogenase, methenyltetrahydrofolate-cyclohydrolase, formyltetrahydrofolate synthetase. J Biol Chem. 1998;263:15946–50.
16.
Wang N, Zhang H, Yao Q, Wang Y, Dai S, Yang X. TGFBI promoter hypermethylation correlating with paclitaxel chemoresistance in ovarian cancer. J Exp Clin Cancer Res. 2012;31:6.PubMedCentralPubMedCrossRef
17.
Duthie SJ. Folic acid deficiency and cancer: mechanisms of DNA instability. Br Med Bull. 1999;55:578–92.PubMedCrossRef
18.
19.
Laatio L, Myllynen P, Serpi R, Rysä J, Ilves M, Lappi-Blanco E, et al. BMP-4 expression has prognostic significance in advanced serous ovarian carcinoma and is affected by cisplatin in OVCAR-3 cell s. Tumor Biol. 2011;32:985–95.CrossRef
20.
Guan X, Zhang N, Yin Y, Kong B, Yang Q, Han Z, et al. Polymorphisms in the p63 and p73 genes are associated with ovarian cancer risk and clinicopathological variables. J Exp Clin Cancer Res. 2012;31:89.PubMedCentralPubMedCrossRef
21.
Brody LC, Conley M, Cox C, Kirke PN, McKeever MP, Mills JL. A polymorphism, R653Q, in the trifunctional enzyme methylenetetrahydrofolate dehydrogenase/methenyltetrahydrofolate cyclohydrolase/formyltetrahydrofolate synthetase is a maternal genetic risk factor for neural tube defects: report of the Birth Defects Research Group. Am J Hum Genet. 2002;71:1207–15.PubMedCentralPubMedCrossRef
22.
Chen LH, Liu ML, Hwang HY, Chen LS, Shane B. Human methionine synthase: cDNA cloning, gene localization, and expression. J Biol Chem. 1997;272:3628–34.PubMedCrossRef
23.
Kelemen LE, Goodman MT, McGuire V, Rossing MA, Webb PM, Köbel M, et al. Genetic variation in TYMS in the one-carbon transfer pathway is associated with ovarian carcinoma types in the Ovarian Cancer Association Consortium. Cancer Epidemiol Biomarkers Prev. 2010;19:1822–30.PubMedCentralPubMedCrossRef
24.
Granato T, Midulla C, Longo F, Colaprisca B, Frati L, Anastasi E. Role of HE4, CA72.4, and CA125 in monitoring ovarian cancer. Tumor Biol. 2012;33:1335–9.CrossRef
25.
Midulla C, Manganaro L, Longo F, Viggiani V, Frati L, Granato T, et al. HE4 combined with MDCT imaging is a good marker in the evaluation of disease extension in advanced epithelial ovarian carcinoma. Tumor Biol. 2012;33:1291–8.CrossRef
26.
Xu Y, Li Q, Li XY, Yang QY, Xu WW, Liu GL. Short-term anti-vascular endothelial growth factor treatment elicits vasculogenic mimicry formation of tumors to accelerate metastasis. J Exp Clin Cancer Res. 2012;31:16.PubMedCentralPubMedCrossRef
27.
Smoter M, Bodnar L, Grala B, Stec R, Zieniuk K, Kozlowski W, et al. Tau protein as a potential predictive marker in epithelial ovarian cancer patients treated with paclitaxel/platinum first-line chemotherapy. J Exp Clin Cancer Res. 2013;32:25.PubMedCentralPubMedCrossRef
28.
Macuks R, Baidekalna I, Donina S. An ovarian cancer malignancy risk index composed of HE4, CA125, ultrasonographic score, and menopausal status: use in differentiation of ovarian cancers and benign lesions. Tumor Biol. 2012;33(5):1811–7.CrossRef
29.
30.
Zhang H, Qi C, Wang A, Yao B, Li L, Wang Y, et al. Prognostication of prostate cancer based on NUCB2 protein assessment: NUCB2 in prostate cancer. J Exp Clin Cancer Res. 2013;32:77.PubMedCentralPubMedCrossRef
Metadata
Title
Lack of association between MTHFD1 G401A polymorphism and ovarian cancer susceptibility
Authors
Yuling Cui
Yanhua Jing
Zihan Sun
Publication date
01-04-2014
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 4/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-1446-z

Other articles of this Issue 4/2014

Tumor Biology 4/2014 Go to the issue

Research Article

The prognostic value of Smad4 mRNA in patients with prostate cancer

Research Article

Lack of association between interleukin-4 −524C>T polymorphism and colorectal cancer susceptibility

Research Article

MicroRNA218 inhibits glioma migration and invasion via inhibiting glioma-associated oncogene homolog 1 expression at N terminus

Research Article

Filamin A regulates MMP-9 expression and suppresses prostate cancer cell migration and invasion

Research Article

Clinicopathological and prognostic significance of chemokine receptor CXCR4 overexpression in patients with esophageal cancer: a meta-analysis

Research Article

Urinary transforming growth factor α and serum α-fetoprotein as tumor markers of hepatocellular carcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits